Prosensa rises as sell-side begins to digest FDA stance on Sarepta's eteplirsen

|About: Prosensa Holding N.V. (RNA)|By:, SA News Editor

Prosensa (RNA) rallies 11% in premarket trading.

The shares are likely responding to news that the FDA currently considers an NDA for Sarepta's (SRPT) eteplirsen to be premature.

Worth noting: The FDA's commentary on drisapersen wasn't exactly upbeat, but bad news for SRPT is considered good news for RNA as the companies are developing potentially competing DMD treatments.

The sell-side is beginning to weigh in on the eteplirsen news. Citi reportedly thinks SRPT could trade between $10-20 on the news (a pretty good bet considering it's already trading below $20 before the bell) as the company attempts to devise suitable endpoints, while Canaccord flags heightened regulatory and clinical risk.

SRPT now -54%